Genotyping and treatment issues with 'unusual' HCV 1 subtypes.

Area of Science:

• Virology
• Infectious Diseases
• Genomics

Background:

• Uncommon Hepatitis C Virus (HCV) subtypes, specifically non-1a/1b, are frequently observed in Sub-Saharan Africa.
• These HCV variants possess natural resistance-associated substitutions within the NS5A region, complicating characterization and treatment.
• The prevalence of these difficult-to-treat subtypes necessitates improved diagnostic and therapeutic strategies.

Purpose of the Study:

• To report HCV genome sequences from African patients with rare subtypes 1g and 1e.
• To evaluate the effectiveness of the pangenotypic regimen sofosbuvir/velpatasvir in treating these unusual HCV subtypes.
• To identify the most suitable genomic region for accurate subtyping and informed treatment decisions.

Main Methods:

• Whole genome sequencing of HCV from two African subjects with unusual subtypes 1g and 1e.
• Analysis of HCV genome sequences from a subtype 1 reference panel.
• Utilizing multiple bioinformatics tools for precise HCV subtyping.

Main Results:

• One patient with unusual subtype 1e experienced treatment failure with sofosbuvir/velpatasvir.
• Sequence analysis indicated that the NS5A region is highly effective for identifying unusual HCV subtypes.
• The NS5A region's polymorphisms are crucial for understanding treatment resistance.

Conclusions:

• The NS5A region is the most reliable target for detecting and characterizing unusual HCV subtypes prevalent in Sub-Saharan Africa.
• Accurate NS5A-based subtyping can significantly assist in selecting appropriate treatment regimens for these challenging cases.
• Further research is needed to optimize treatment strategies for patients infected with non-1a/1b HCV subtypes.